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ABSTRACT
The use of opioids in the treatment of chronic
pain is widespread; the prevalence of specific
opioids varies from country to country and
depends on product availability, national
formulary systems, and provider preferences.
Patients often receive opioids for legitimate
treatment of pain conditions, but on the
opposite side of the spectrum, nonmedical use
of opioids is a significant public health concern.
Opioids are associated with several side effects,
and constipation is the most commonly reported
and persistent symptom. Unlike some adverse
effects associated with opioid use, tolerance does
not develop to constipation. Opioid-induced
constipation (OIC) is the most prevalent
patient complaint associated with opioid use
and has been associated with declines in various
quality of life measures. OIC can be extremely
difficult for patients to tolerate and may prompt
patients to decrease or discontinue opioid
treatment. Current management strategies for
OIC are often insufficient. A prolonged-release
formulation of oxycodone/naloxone (OXN) has
been investigated for the treatment of
nonmalignant and cancer pain and mitigation
of OIC, and evidence is largely favorable. Studies
have demonstrated the capability of OXN to
alleviate OIC while maintaining pain control
comparable to oxycodone-only regimens. There
is insufficient evidence for OXN efficacy for
patients with mild OIC or patients maintained
on high doses of opioids, and use in these
populations is controversial. The reduction of
costs associated with OIC may provide overall
cost effectiveness with OXN. Additionally, the
presence of naloxone may deter abuse/misuse by
those seeking to misuse the formulation by
modes of administration other than oral
ingestion. Most studies to date have occurred in
European countries, and phase 3 trials continue
in the United States. This review will include
current therapeutic options for pain and
constipation, unique characteristics of OXN,
evidence related to use of OXN and its place in
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therapy, discussion of opioid abuse/misuse, and
various abuse-deterrent mechanisms, and areas
of continuing research.
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INTRODUCTION
Chronic nonmalignant pain is experienced by
20–40% of adults, and cancer pain by up to 70%
of oncology patients [1, 2]. Opioids are
routinely employed in pain treatment for both
etiologies, despite a lack of data to characterize
potential implications of long-term use for
nonmalignant pain [1, 3]. The United States
(US) ranks 3rd for opioid consumption per
capita, with hydrocodone and oxycodone
most commonly prescribed [4]. Despite
increasing use of opioid analgesics, pain is still
frequently undertreated in the US and around
the world [4, 5].
Oxycodone/naloxone (OXN) prolonged-
release (PR) is indicated for treatment of severe
pain requiring treatment with opioids; a low
dose of naloxone added to the fixed-dose
combination (FDC) antagonizes opioid
receptors in the gastrointestinal tract,
providing relief of opioid-induced constipation
(OIC) [6]. OXN is the first product with a dual
mechanism for achieving opioid analgesia
while targeting the underlying cause of OIC,
thus proactively addressing constipation
symptoms. OXN was initially approved in
Germany in 2006 and is now approved for use
in 36 countries. Currently, it is under review by
the Food and Drug Administration for approval
in the US [7]. This review will explore the utility
of OXN for use in pain management while
providing relief of OIC, and implications of
potential abuse deterrence.
METHODS
A literature search was conducted in the
MEDLINE database using term ‘‘oxycodone
and naloxone’’ through December 2013. All
clinical and pharmacokinetic studies and
reviews of OXN (as the FDC or separate
formulations) were included. The MEDLINE
search generated 177 results, with 59
containing relevant information for OXN. A
search on clinicaltrials.gov for ‘‘oxycodone and
naloxone’’ was performed in December 2013,
and additional references were identified in
published bibliographies. This review does not
contain any new studies with human or animal
subjects performed by any of the authors.
OPIOID-INDUCED CONSTIPATION
Opioids are well known for causing
gastrointestinal disturbances, including
nausea, vomiting, and constipation [8]. OIC is
primarily caused by stimulation of opioid
receptors in the gastrointestinal tract, resulting
in relaxation of the colon and small intestine
due to anticholinergic mechanisms, decreased
motility, reduced secretions, and extended
transit time of gastrointestinal contents [9,
10]. These factors contribute to symptoms
such as constipation, gastroesophageal reflux,
bloating, and abdominal cramping, a
constellation of symptoms referred to as
opioid-induced bowel dysfunction (OIBD) [10].
Constipation is the most commonly reported
adverse effect of opioids, affecting an estimated
40% of patients with nonmalignant pain and
70–95% of patients with cancer pain [10–12].
Unlike other side effects associated with
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opioids, constipation does not typically resolve
with continued use [8, 13–24]. Although the
interaction of opioids with the enteric nervous
system is primarily responsible for OIC, there is
evidence of a centrally mediated component as
well [11, 25, 26]. Intraspinal administration of
opioids has been shown to delay gastric
emptying and prolong intestinal transit time,
and research indicates possible differences in
receptor mechanisms and sites (peripheral
versus central) within the opioid class [26–30].
At this time, the full impact of centrally
medicated OIC is unclear, as gastrointestinal
function correlates more closely with opioid
concentrations in the enteric nervous system
than in the central nervous system (CNS)
[11, 18].
OIC has been linked to higher healthcare
costs ranging from $4,880 to $36,152 per
patient, lower work productivity, and declines
in quality of life measures [10–15, 31, 32]. The
negative impact and incidence of opioid-related
side effects may be underestimated by
practitioners. More than half of chronic pain
patients rate constipation as at least moderately
bothersome compared to side effects unrelated
to gastrointestinal function [33]. Due to the
intolerability of OIC, patients may
unsuccessfully adjust or discontinue their
regimen in attempt to improve bowel
symptoms [31–33]. Because OIC occurs at
lower doses than those needed for pain
control, tapering the dose may not resolve
OIC or allow for sufficient analgesia [16]. Some
practitioners have suggested opioid rotation to
transdermal routes, but this does not reliably
lessen the burden of OIC [17]. Overall, the
impact of OIBD and OIC may be
underappreciated [18]; appropriate steps must
be taken to address these symptoms to
maximize opportunity for patient adherence
and pain management.
TREATMENT OF OIC
Prevention of OIC is considered more effective
for patients on chronic opioid treatment, yet
OIC is often managed in a reactive fashion [1,
19]. Nonpharmacological interventions (e.g.,
fluid and fiber intake), laxatives, and stool
softeners used for prevention or treatment of
OIC do not adequately address the underlying
mechanisms and are unsuccessful for many
patients [19–21]. Up to half of patients with
OIC treated with laxatives will fail to reach
treatment goals [21, 22]. Treatment guidelines
for both cancer and nonmalignant pain have
recommended prophylactic laxatives for
patients treated with opioids, but to date there
is a lack of quality evidence regarding efficacy or
safety [23, 24, 34]. Prolonged use of laxatives
can contribute to tissue or nerve damage in the
gastrointestinal tract, loss of vitamins or
minerals, kidney stones, or renal failure [35].
Medications approved for the treatment of
chronic idiopathic constipation, such as
prucalopride and lubiprostone, have
insufficient data supporting efficacy for OIC,
and more research is needed [36].
The peripheral l-opioid receptor antagonists
alvimopan and methylnaltrexone are used to
ameliorate the gastrointestinal effects of opioids.
Both medications antagonize opioid receptors in
the gastrointestinal tract but not the CNS; the
net effect is a reduction in OIBD symptoms while
sparing opioid analgesia [11]. Despite their
effectiveness, both are restricted to very specific
indications that limit broad application.
Methylnaltrexone is approved in Canada, US,
and the European Union for the treatment of
OIC in patients with advanced illness receiving
palliative care that have not responded to
treatment with laxatives [37]. Methylnaltrexone
is administered subcutaneously and, according
to the manufacturer, has not been studied for use
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exceeding 4 months duration [38]. Oral
formulations with enteric coating are currently
under development [39, 40]. Alvimopan is
indicated for short-term use in hospitalized
patients following bowel resection surgery to
reduce postoperative ileus. Adverse effects such
as cardiovascular events, neoplasms, and
fractures have been observed during treatment
with alvimopan; it also does not hold an
indication for OIC and studies for this
condition have been limited [35, 37]. Due to
safety considerations, use of alvimopan in the US
is restricted to registered hospitals in the Entereg
Access Support and Education (E.A.S.E.TM)
program [37, 41]. While the use of peripheral
opioid antagonists can be an effective strategy
for managing opioid-induced gastrointestinal
effects, some experts have proposed that
response rates may be incomplete due to the




OXN is supplied in the following combinations
of oxycodone/naloxone: 5/2.5 mg, 10/5 mg,
20/10 mg, 40/20 mg. The usual starting dose is
10/5 mg every 12 h and the maximum daily dose
is 80/40 mg. Naloxone undergoes significant
first-pass intestinal and hepatic metabolism
to inactive metabolites, primarily by
glucuronidation by uridine 50-diphospho-
glucuronosyltransferases (UGT) 1A8 and 2B7,
with a lesser role for N-dealkylation by
cytochrome P450 (CYP) 3A4 [44, 45]. Very little
naloxone reaches the systemic circulation,
accounting for its very low oral bioavailability
(2–3%). Thus, clinically significant systemic
exposure does not occur following oral
administration, allowing localized gastrointestinal
antagonism without reversal of analgesia
[20, 46]. Nevertheless, prior experience
with immediate-release (IR) formulations
of naloxone indicated precipitation of
withdrawal symptoms, even at low doses [20,
47, 48]. It has been proposed that naloxone IR
may saturate metabolism capacity, facilitating
systemic absorption and reversal of opioid
agonism [10, 13]. Consequently, OXN uses a
PR formulation for both oxycodone and
naloxone, which may limit systemic exposure
of naloxone. Naloxone demonstrably reduces
colonic transit time, and studies have indicated
bioavailability equivalence between the
individual components and the FDC [6, 49,
50]. An optimized balance of efficacy for OIC
and limiting undesired gastrointestinal
symptoms (e.g., abdominal pain, diarrhea)
occurs with an oxycodone to naloxone ratio of
2:1 [13, 51].
OXN underwent several key randomized
controlled trials (RCTs) in Europe
demonstrating similar analgesic outcomes to
oxycodone PR as well as efficacy for OIC (see
Table 1 for key studies). Most studies included
patients with chronic nonmalignant pain [13,
52–55]. RCTs compared OXN to placebo and
oxycodone PR, but comparisons to other PR
opioid analgesics have not been performed.
OXN impact on OIC was primarily
demonstrated by improved scores on the
Bowel Function Index (BFI), as well as other
measures including complete spontaneous
bowel movements (CSBM), Patient Assessment
of Opioid-Induced Constipation, Patient
Assessment of Constipation Symptoms,
frequency of laxative use, and stool
consistency on the Bristol Stool Form scale
[13, 52–54, 56]. A BFI score is the mean of
three patient-scored components for bowel
dysfunction (1–100), with higher scores
indicating greater dysfunction [57]. Differences
between OXN and its comparators were assessed
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for impact on OIC based on statistical
significance and also clinical relevance: a BFI
score [28.8 represents constipation, while a
reduction C12 has been validated as a clinically
meaningful change [57, 58]. CSBMs should
exceed three per week, with fewer representing
constipation based on Rome III criteria [59].
Phase 3 trials indicated both statistically
significant and clinically relevant gains in
bowel function with OXN, with three trials
indicating benefit within the first week of
treatment [13, 53, 54, 56]. An extended and
persistent benefit of OXN for bowel dysfunction
has been demonstrated during open-label
treatment for 12 months, with mean BFI score
further lowered below levels associated with
constipation (from 35.6 to 20.6) [60]. In all
RCTs except one [13], mean BFI score following
4 to 12 weeks of treatment with OXN was still
higher than 28.8, indicating persistence of
symptoms [13, 53, 54, 56, 61]. It is important
to note some patients had very high BFI scores
prior to treatment with OXN and experienced
substantial decreases in this parameter overall.
Though OXN may have mitigated OIC,
constipation may have persisted in some
patients due to confounding factors such as
metabolic disorders, hydration status, age,
comorbidities, and medications [31]. Likewise,
OXN treatment decreased but did not eliminate
need for laxatives, with 34–70% of patients
presenting with OIC still requiring adjunct
therapy after 4 weeks of OXN [13, 53, 54, 61].
Prolonged treatment may facilitate
reductions in laxative dependence, as 16% of
patients in the extension phase used laxatives
with only 8.7% reporting regular laxative use
[60]. Use of laxatives between treatment arms
did not achieve statistically significant
differences in RCTs enrolling patients with
cancer pain or those lacking constipation at
baseline [56, 62].
Although results of RCTs indicate
comparable analgesic efficacy of OXN to
oxycodone PR, noninferiority has not been
unequivocally demonstrated. Four trials
attempted to demonstrate noninferiority of
OXN or co-administration of oxycodone and
naloxone for analgesia, but failed to establish
the boundary for inferiority or achieve adequate
power in study design [13, 56, 61, 63].
Calculated P values between treatment arms of
OXN and oxycodone PR did not achieve
statistical significance, indicating failure to
reject the null hypothesis for superiority rather
than illustrating equivalence or noninferiority
[64, 65]. Despite this limitation, patient and
provider preference for efficacy and tolerability
indicate preference for OXN versus oxycodone
PR [55]. Several observational studies have
demonstrated successful use of OXN in clinical
practice for a large number of patients,
including geriatric populations [9, 60, 66–70].
OXN is an effective analgesic for treatment of
neuropathic pain, which is notoriously difficult to
treat [62, 67, 69]. Three published studies have
addressed use of OXN for postoperative pain
following orthopedic, gynecological, and cardiac
surgery, with mixed results [63, 71, 72].
Improvement in bowel function has not been
unequivocally demonstrated, potentially
complicated by the low doses and brief
treatment courses used and impact of
gastrointestinal surgery on bowel function;
analgesia was similar to intravenous (IV) opioids
[63, 71, 72]. OXN is not recommended before
surgery or for 12 to 24 h in the immediate
postoperative period [46]. Three studies to date
have focused on patients with cancer pain, with
only one designed as a RCT [56] and two as
observational studies [9, 68]. Although OXN
exhibited favorable outcomes for analgesic
efficacy, several questions have been raised
regarding its place in therapy for this indication.
Pain Ther (2014) 3:1–15 7
Patients treated for cancer pain may require high
doses and rapid titration, and the maximum OXN
dose of 80/40 mg per day may preclude effective
treatment [9, 73]. Furthermore, constipation in
cancer patients is often multifactorial, and the
benefit of OXN for ameliorating symptoms of
OIBD may be limited [10, 12]. An observational
study by Cuomo et al. [68] demonstrated that
4 weeks of treatment with OXN for cancer pain
did little to improve BFI scores, although it did
not worsen pre-existing bowel dysfunction.
The primary adverse effect associated with
OXN was gastrointestinal in nature (e.g., diarrhea,
constipation, abdominal pain, and nausea).
Symptoms exhibited a dose-related increase in
prevalence over placebo and oxycodone PR in
RCTs, but OXN has an overall adverse effect and
safety profile similar to oxycodone PR at doses
studied [13, 52–54]. Gastrointestinal symptoms
may represent a return of bowel function and
have been described following treatment with
methylnaltrexone [13, 38]. Four RCTs [52, 54, 56,
62] and one observational study [60] monitored
opioid withdrawal symptoms via the modified
Subjective Opioid Withdrawal Scale; the addition
of naloxone does not appear to precipitate opioid
withdrawal, and adverse effects consistent with
withdrawal were generally comparable between
groups. Open-label extension studies up to
52 weeks have maintained a favorable
tolerability profile, with higher rates of adverse
effects observed in the first 3 months and few
serious adverse effects [60, 61].
PHARMACOECONOMIC
CONSIDERATIONS
Results from industry-sponsored cost-
effectiveness analyses favored OXN over
oxycodone PR in the United Kingdom (UK),
Germany, Spain, Belgium, and the Netherlands
[74–78]. The German study [76, 77] used a
noninterventional design and compared
treatment with OXN versus other strong
opioids (World Health Organization Step III),
yielding an incremental cost-effectiveness ratio
(ICER) that demonstrated greater cost
effectiveness with OXN. Broad applicability of
these results may be limited, given that annual
acquisition costs were higher for other opioids
compared to OXN and no statistically
significant difference was noted in quality-
adjusted life years in the 6-month interim
analysis [76, 77]. Despite higher direct costs of
OXN treatment in the UK and Spain, both
studies demonstrated ICER values below
thresholds used to determine cost efficiency
[74, 75]; similar findings were published for
Belgium and the Netherlands [78]. These studies
support that overall cost savings may be
achieved when OXN is selected for some
patients with OIC, as the cost of drug
acquisition may be offset by costs associated
with complications of OIBD. Of note, data were
pulled from previous clinical trials which
restricted laxative use [74, 78].
Recommendations for scheduled laxatives with
chronic opioid therapy are routine but not
always followed [19]. Published RCT protocols
deviated from this standard of care [53, 54], but
may better reflect real-world scenarios in which
laxatives are frequently used reactively [19, 74].
A direct cost comparison of OXN to a regimen
with PR opioids and scheduled laxatives has not
been performed [13, 53–56].
PLACE IN THERAPY
Overall, OXN appears to exhibit a favorable
risk/benefit profile for achieving analgesic
efficacy while preventing and treating—but
not completely alleviating—symptoms of OIC.
Clinical trials indicate improved outcomes for
OIC when patients are constipated at baseline,
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but there may be questionable benefit in
patients with limited or no symptoms of OIC.
Only two RCTs included patients who did not
have OIC at baseline [52, 62]. OXN treatment
did not achieve statistically significant
outcomes on bowel function in either study,
but neither used BFI score as a primary endpoint
and constipation may not have been related to
opioid use in one study [52, 62]. The number
needed to treat (NNT) for patients with existing
OIC to achieve at least 3 CSBMs per week was
3.8 to 4 in clinical trials [53, 54], whereas the
NNT for patients with mild or no existing OIC
was 14 [52, 79]. While prophylaxis with a
laxative-based bowel regimen (the current
standard of care) may not always be effective,
the NNT for preventing a C72 h period without
a CSBM has been demonstrated between 2.9
and 4.8; however, magnesium oxide was the
most common laxative used in these trials, in
contrast to senna or bisacodyl which are the
most conventional laxatives used in the US [22,
80]. Clinicians must weigh the risks and benefits
of treating patients prophylactically with OXN
for as-yet-undeveloped OIC, although some
experts have recommended prevention with
OXN [18, 81].
There is insufficient data to evaluate whether
patients requiring high doses of opioids may be
effectively treated with OXN. Earlier studies in
patients with nonmalignant pain investigated
lower doses (typically a maximum of 40/20 mg
to 80/40 mg per day) [9, 13, 52, 53, 55, 60, 66].
Only two RCTs have investigated doses up to
120/60 mg/day [54, 56], and one observational
study maximized doses at 160/80 mg [68].
Oxycodone CR may be given as supplemental
doses up to 400 mg/day when analgesic
requirements are increased, but this may
negate the benefit of naloxone for OIC [46].
Although studies of naloxone 5–120 mg have
demonstrated bioavailability of B2%, concern
exists surrounding the notion that increased
doses may facilitate greater absorption of
naloxone, precipitating opioid withdrawal or
loss of analgesia [82, 83]. Two case reports of
treatment failure with OXN have been
published. In the first case [73], conversion
and titration from oxycodone PR 40 mg/day to
OXN 240/120 mg/day over 4 days resulted in
poor analgesia, possibly indicating a role for
high-dose OXN or rapid titration in treatment
failure [84, 85]. In the second report [86], poor
analgesia and symptoms of withdrawal were
documented in a patient with portal vein
thrombosis after converting oxycodone PR to
OXN 20/10 mg/day. The authors hypothesized
that absorption of naloxone via portosystemic
collateral channels bypassed first-pass hepatic
metabolism, resulting in increased
bioavailability of naloxone [86]. These cases
support employing vigilance when prescribing
OXN to patients requiring high doses or rapid
titration. OXN is contraindicated in patients
with moderate to severe hepatic impairment as
systemic exposure with naloxone may be
increased. Additionally, OXN has not been
studied in pregnant or lactating women.
Naloxone crosses the placenta, and fetal
exposure could result in opioid withdrawal [46].
OXN use has been explored for other
conditions, including restless leg syndrome
symptoms refractory to first-line dopaminergic
treatment [87]. Studies for use with other
indications have been recently completed
or are underway (e.g., Clinicaltrials.gov
#NCT01197261, #NCT01374763, #NCT01816581,
#NCT01439100, #NCT00944697).
OPIOID MISUSE AND ABUSE
DETERRENCE
In light of increasing levels of nonmedical use,
the risks and benefits of prescribing controlled
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substances must always be carefully considered
[88, 89]. Individuals may abuse opioids via
several different modes of administration, with
oral, IV, and intranasal identified as the most
common routes [90]. Some formulations readily
lend themselves to overuse via the intended
route (e.g., IR oxycodone and hydrocodone).
Other medications are appealing due to the
ability of users to overcome the PR mechanisms
to achieve a better ‘‘high’’ by administration
through an alternative route. Experienced
opioid abusers are known to tamper with
formulations to accelerate drug delivery by
injection or insufflation, but the oral route is
preferred by the vast majority (up to 97% of
abusers) [90]. Abusers have identified
oxycodone as a drug of preference due to its
variety of available formulations [91];
consequently, abuse-deterrent formulations
such as OXN may be of great clinical
importance.
Abuse-deterrent strategies are typically
targeted at discouraging tampering attempts
and limiting administration by non-approved
routes such as injection, which may carry
increased risks to the abuser (e.g., overdose,
infection, drug dependence) [92]. Tamper
resistance (i.e., physical barriers), inclusion of
irritants, aversive components, formulation of a
prodrug, and unique delivery systems are all
employed in efforts to dissuade abuse [93, 94].
Combining an opioid agonist with an
antagonist may discourage tampering or
administration by unapproved routes [90, 94].
It is important to note that abuse-deterrent
mechanisms do not preclude all forms of abuse
and may lead to unpredictable upswings in
abuse of other drugs [95, 96]. Furthermore, the
addition of an orally inactive antagonist may
not discourage abuse by oral ingestion [97].
Abuse-deterrent mechanisms are, however, an
important component of efforts to dissuade
nonmedical use and limit ingestion by high-risk
routes of administration. It has been suggested
that OXN may provide abuse deterrence,
though no peer-reviewed studies are available
as of this writing. It has been suggested that
increased systemic exposure of naloxone,
antagonism of opioid effects, and reduced
drug liking when the drug is chewed or
administered via intranasal and IV routes may
reduce the appeal of OXN for experienced
opioid abusers [98–101]. The manufacturer is
seeking language about abuse deterrence on the
product label in the US [7].
CONCLUSIONS
OXN is a promising addition to the
armamentarium of treatment options for
chronic pain of cancer and nonmalignant
etiology. Naloxone does not appear to impair
analgesic efficacy for the vast majority of
patients, and benefit for the treatment of OIC
has been clearly demonstrated. The role for
OXN in OIC prevention compared to standard
prophylaxis with laxatives has yet to be
determined. OXN use for prevention in at-risk
populations may be prudent given the high
burden and relative under-appreciation of OIC’s
impact, and provide greater cost efficiency by
reducing costs associated with OIC. As
prescription drug misuse with oxycodone and
other opioids has grown to epidemic
proportions in the US, the presence of
naloxone as an abuse-deterrent feature may
potentially confer additional benefit,
particularly for oxycodone abusers who prefer
non-oral routes of ingestion. It is unclear how
the presence of naloxone will affect abusers who
prefer to ingest large quantities of the drug
orally. More research on the impact of abuse
deterrence for this formulation is needed.
10 Pain Ther (2014) 3:1–15
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